Arabic Arabic English English French French German German
dark

Bionomics Receives FDA Clearance of IND for Evaluation of BNC210 in a Phase 2 Social Anxiety Disorder PREVAIL Study

Bionomics Limited, a clinical-stage biopharmaceutical company, is pleased to announce that it has received U.S. Food and Drug Administration clearance to proceed with evaluating its lead clinical compound, BNC210, for the acute treatment of Social Anxiety Disorder in a Phase 2 clinical trial named the PREVAIL Study. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study

Next Post

NLS Pharmaceutics CEO Issues Letter to Shareholders

Related Posts
Total
0
Share